HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced it will host a conference call on Aug. 13 at 4:30 p.m. ET to discuss financial results for the second quarter ended June 30, 2026, and provide updates on its strategy to accelerate global adoption of its ambulatory ECG signal platform. The call will be led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic and Chief Financial Officer Timothy Cruickshank, and will include a question-and-answer session following prepared remarks.
The company is developing a cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, redefining the future of cardiac health management.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. For investors, the latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
The upcoming call provides an opportunity for investors and industry observers to gain insight into HeartBeam’s financial performance and strategic direction. The company’s focus on ambulatory ECG monitoring addresses a growing need for remote cardiac care solutions, particularly as healthcare systems seek to reduce hospital visits and enable earlier detection of cardiac events.
HeartBeam’s technology, which received FDA clearance for arrhythmia assessment and 12-lead ECG synthesis, positions the company to compete in the expanding market for wearable cardiac devices. The ability to capture 3D ECG signals without cables could offer advantages over traditional Holter monitors and other ambulatory ECG devices, potentially improving patient compliance and diagnostic accuracy.
The conference call will likely highlight milestones in commercial adoption, reimbursement strategies, and partnerships. Given the FDA clearances obtained in 2024 and 2025, the company is now focused on driving adoption among healthcare providers and patients. The second-quarter results will provide a baseline for assessing progress.
For leaders in business and technology, HeartBeam’s progress illustrates the convergence of medical device innovation and digital health. The platform’s ability to synthesize 12-lead ECG data from a compact, cable-free device could reduce the cost and complexity of cardiac monitoring, making it more accessible. As remote patient monitoring becomes increasingly important, HeartBeam’s strategy to accelerate global adoption will be closely watched.
More details about the company’s cleared indications for use are available at https://www.heartbeam.com/indications. The full press release can be accessed at https://ibn.fm/sqGLs.
